Pro-gastrin-releasing peptide in patients with benign and malignant diseases

Tumor Biology

Volumn 25, Issue 1-2, 2004, Pages 56-61

  Molina, Rafael ^a   Auge, Jose M ^a   Alicarte, Julian ^a   Filella, Xavier ^a   Viñolas, Nuria ^a   Ballesta, Antonio M ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Lung cancer; Neurospecific enolase; Pro gastrin releasing peptide; Small cell lung cancer; Tumor marker

Indexed keywords

GASTRIN RELEASING PEPTIDE DERIVATIVE; PROGASTRIN RELEASING PEPTIDE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; KIDNEY FAILURE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 3042552039     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077724     Document Type: Article

References (37)

1. Kibbellar RE, Moolenaar KEC, Michalides RJ, van Bodegom PC, Vanderschueren RG, Vagenaar SS, Dingemans KP, Bitter-Suermann D, Dalesio O, van Zandwijk N: Neural cell adhesion molecule expression, neuroendocrine differentiation and prognosis in lung carcinoma. Eur J Cancer 1991;27:431-435.
2. Cooper EH, Splinter TAW, Brown DA, Muers MF, Peake MD, Pearson SL: Evaluation of a radioimmunoassay for neuron-specific enolase in small cell lung cancer. Br J Cancer 1985;52:333-338.
3. Fischbach W, Schwarz-Wallrauch C, Jany N: Neuron-specific enolase and thymidine kinase as an aid to the diagnosis and treatment monitoring of small cell lung cancer. Cancer 1989;63:1143-1149.
4. Jorgensen lG, Hansen HH, Cooper EH: Neuron specific enolase, carcinoembryonic antigen and lactate dehydrogenase as indicators of disease activity in small cell lung cancer. Eur J Cancer Clin Oncol 1989;25:123-128.
5. Niho S, Nishiwaki Y, Goto K, Ohmatsu H, Matsumoto T, Hojo F, Ohe Y, Kakinuma R, Kodama T: Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: Comparative evaluation with neuron-specific enolase and carcinoembryonic antigen. Lung Cancer 2000;27:159-167.
6. Shibayama T, Ueoka H, Nishii K, Kiura K, Tabata M, Miyatake Y, Harada M: Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small cell lung cancer (SCLC). Lung Cancer 2001;32:61-69.
7. Viñolas N, Molina R, Galan MC, Casas F, Callejas MA, Filella X, Grau JJ, Ballesta AM, Estape J: Tumor markers in response monitoring and prognosis of non-small cell lung cancer: Preliminary report. Anticancer Res 1998;18:631-634.
8. Stieber P, Dinemann H, Schalhorn A, Schmitt UM, Reinmiedl J, Hofmann K, Yamaguchi K: Pro-gastrin-releasing peptide (ProGRP) - a useful marker in small cell lung carcinomas. Anticancer Res 1999;19:2673-2678.
9. Berendsen HH, de Leij L, Poppema S, Postmus PE, Boes A, Sluiter HJ: Clinical characterization of non-small-cell-lung cancer. Tumors showing neuroendocrine differentiation features. J Clin Oncol 1989;7:1614-1620.
10. Nobels FR, Kwekkeboom DJ, Copmans W, Schoenmakers CH, Lindemans J, De Herder WW, Krenning EP, Bouillon R, Amberts SW: Chromogranin A as serum marker for neuroendocrine neoplasia: Comparison with neuronspecific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997;82:2622-2628.
11. Lamy PJ, Grenier J, Kramar A, Pujol JL: Progastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer. Lung Cancer 2000;29:197-203.
12. McDonald TJ, Nilsson G, Vagne M, Ghatei M, Bloom SR, Mutt V: A gastrin releasing peptide from the porcine nonantral gastric tissue. Gut 1978;19:767-774.
13. Yamaguchi K, Abe K, Kamoya T, Kameya T, Adachi I, Taguchi S, Otsubo K, Yanaihara N: Production and molecular size heterogeneity of immunoreactive gastrin-releasing peptide in fetal and adult lungs and primary lung tumors. Cancer Res 1983;43:3932-3939.
14. Holst JJ, Hansen M, Bork E, Schwartz T: Elevated plasma concentrations of C-flanking gastrin-releasing peptide in small-cell lung cancer. J Clin Oncol 1989;7:1831-1838.
15. Maruno K, Yamaguchi K, Abe K, Suzuli M, Saijo N, Mishima Y, Yanaihara N, Shimosato Y: Immunoreactive gastrin-releasing peptide as a specific tumor marker in patients with small cell lung carcinoma. Cancer Res 1989;49:629-632.
16. Aoyagi K, Miyake Y, Urakami K, Kashiwakuma T, Hasegawa A, Kodama T, Yamaguchi K: Enzyme immunoassay of immunoreactive progastrin-releasing peptide (31-98) as tumor marker for small cell lung carcinoma: Development and evaluation. Clin Chem 1995;41:537-543.
17. Yamaguchi K, Aoyagi K, Urakami K, Fukutani T, Maki N, Yamamoto S, Otsubo K, Miyake Y, Kodama T: Enzyme-linked immunoabsorbant assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement. Jpn J Cancer Res 1995;86:698-705.
18. Goto K, Kodama T, Hojo F, Kubota K, Kahinuma R, Matsumoto T, Ohmatsu H, Sekine I, Nagai K, Nishiwaki Y: Clinicopathologic characteristics of patients with non-small cell lung carcinoma with elevated serum progastrin-releasing peptide levels. Cancer 1998;82:1056-1061.
19. Takada M, Kusunoki Y, Masuda N, Matui K, Yana T, Ushijima S, Iida K, Tamura K, Komiya T, Kawase I, Kikui N, Morino H, Fukuoka M: Pro-gastrin- releasing peptide (31-98) as a tumour marker of small-cell lung cancer: Comparative evaluation with neuron-specific enolase. Br J Cancer 1996;73:1227-1232.
20. Mountain CF: A new international staging system for lung cancer. Chest 1986;89:225-233.
21. Stahel RA, Ginsberg R, Haveman K, Havemann K, Hirsch FR, Ihde DC, Jassem J: Staging and prognostic factors in small cell lung cancer: A consensus report. Lung Cancer 1989;5:119-126.
22. Pettersson F: Annual Report on the Results of Treatment in Gynecologic Cancer. Stockholm, FIGO Committee on Gynecologic Oncology, 1988.
23. Mastropaolo W, Fernandez Z, Miller EL: Pronounced increases in the concentration of an ovarian tumor marker, CA 125, in serum of a healthy subject during menstruation. Clin Chem 1986;32:2110-2111.
24. Halila H, Stenman UH, Seppala M: Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy. Cancer 1986;57:1327-1329.
25. Duk J, van Voorst Vader PC, Ten Hoor KA, Hollema H, Doeglas HMG, de Bruijn HWA: Elevated levels of squamous cell carcinoma antigen in patients with a benign disease of the skin. Cancer 1989;64:1652-1656.
26. Molina R, Filella X, Torres MD, Ballesta AM, Mengual P, Cases A, Balagué A: SCC antigen measured in malignant and nonmalignant diseases. Clin Chem 1990;36:251-254.
27. Molina R, Filella X, Bruix J, Mengual PJ, Bosch J, Calvet X, Jo J, Ballesta AM: Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem 1991;37:1379-1383.
28. Molina R, Agustí C, Filella X, Jo J, Joseph J, Giménez N, Ballesta AM: Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases. Tumor Biol 1994;15:318-321.
29. Molina R, Agustí C, Mañe JM, Filella X, Jo J, Joseph J, Giménez N, Estapé J, Ballesta AM: CYFRA 21-1 in lung cancer: Comparison with CEA, CA 125, SCC and NSE serum levels. Int J Biol Markers 1994;9:96-101.
30. Molina R, Filella X, Augé JM, Fuentes R, Bover I, Rifa J, Moreno V, Canals E, Viñolas N, Marquez A, Barreiro E, Borras J, Viladiu P: Tumor markers (CEA, CA125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Tumor Biol 2003;24:209-218.
31. Molina R, Filella X, Jo J, Agusti C, Ballesta AM: CA 125 in biological fluids. Int J Biol Markers 1998;13:224-230.
32. Jager W, Kissing A, Cilaci S, Melsheimer R, Lang N: Is an increase in CA 125 in breast cancer patients an indicator of pleural metastases? Br J Cancer 1994;70:493-495.
33. Diez M, Torres A, Maestro ML, Gomez A, Pollan M, Lopez JA, Picardo A, Hernando F, Balibrea JL: Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA 125 and SCC antigens in resectable non-small cell lung cancer. Br J Cancer 1996;73:1248-1254.
34. Molina R, Navarro J, Filella X, Castel T, Ballesta AM: S-100 protein serum levels in patients with benign and malignant diseases: False positive results related to liver and renal function. Tumor Biol 2002;23:39-44.
35. Cases A, Filella X, Molina R, Ballesta AM, Lopez-Pedret J, Revert L: Tumor markers in chronic renal failure and hemodialysis patients. Nephron 1991;57:183-186.
36. Öberg K, Stridsberg M: Neuroendocrine tumors; in Diamandis EP, Fritsche AH, Lilja H, Chan DW, Schwartz MK (eds): Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications. Washington, AACC, 2002, pp 339-349.
37. Creasman WT: New gynecologic cancer staging. Gynecol Oncol 1995;58:157-158.